Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Therapeutic drug monitoring in rheumatic diseases: utile or futile?

Stamp LK, Barclay M.

Rheumatology (Oxford). 2014 Jun;53(6):988-97. Review.

PMID:
24196384
2.

An audit of a therapeutic drug monitoring service for allopurinol therapy.

Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO.

Ther Drug Monit. 2013 Dec;35(6):863-6. doi: 10.1097/FTD.0b013e318299920a.

PMID:
24263644
3.

The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?

Stamp L, Roberts R, Kennedy M, Barclay M, O'Donnell J, Chapman P.

Biomed Pharmacother. 2006 Dec;60(10):678-87. Epub 2006 Oct 20. Review.

PMID:
17071051
4.

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Clin Pharmacol Ther. 2011 Sep;90(3):392-8. doi: 10.1038/clpt.2011.113. Epub 2011 Jul 27.

PMID:
21796116
5.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

PMID:
11961174
6.

[Pharmacological management of inflammatory rheumatic conditions].

Bannwarth B.

Therapie. 2011 Sep-Oct;66(5):377-81. doi: 10.2515/therapie/2011055. Epub 2011 Oct 27. Review. French.

PMID:
22031680
7.

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.

Panomvana D, Sripradit S, Angthararak S.

J Clin Rheumatol. 2008 Feb;14(1):6-11. doi: 10.1097/RHU.0b013e318164dceb.

PMID:
18431090
9.

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).

Furst DE, Keystone EC, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Burmester GR, Crofford LJ, Kavanaugh A.

Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii2-5. Review.

10.
11.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
12.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
13.

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2011 Apr;70(4):583-9. doi: 10.1136/ard.2010.139774. Epub 2011 Feb 17.

14.

The use of conventional disease-modifying anti-rheumatic drugs in established RA.

Jurgens MS, Jacobs JW, Bijlsma JW.

Best Pract Res Clin Rheumatol. 2011 Aug;25(4):523-33. doi: 10.1016/j.berh.2011.10.006. Review.

PMID:
22137922
15.
16.

Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Katchamart W, Trudeau J, Phumethum V, Bombardier C.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008495. doi: 10.1002/14651858.CD008495. Review.

PMID:
20393970
17.

Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.

Keith MP, Gilliland WR.

Clin Pharmacol Ther. 2011 Sep;90(3):363-4. doi: 10.1038/clpt.2011.146.

PMID:
21862966
18.

A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.

Ma MH, Kingsley GH, Scott DL.

Rheumatology (Oxford). 2010 Jan;49(1):91-8. doi: 10.1093/rheumatology/kep331. Epub 2009 Nov 16. Review.

PMID:
19917618
19.

An update on methotrexate.

Braun J, Rau R.

Curr Opin Rheumatol. 2009 May;21(3):216-23. doi: 10.1097/BOR.0b013e328329c79d. Review.

PMID:
19373092
20.

Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.

[No authors listed]

Prescrire Int. 2010 Feb;19(105):30-4. Review.

PMID:
20455343

Supplemental Content

Support Center